Discover
KURA
Kura Oncology, Inc.
10.78
2 x 7.96
2 x 13.74
bid
ask
-
0.19
1.73%
2 @ 05:17 AM
10.89 +0.11 (1.02%)
| Ytd | 3.75% | |
| 1y | 92.50% |
10.70
day range
11.18
5.45
52 week range
12.49
| Open | 10.98 | Prev Close | 10.97 | Low | 10.70 | High | 11.18 | Mkt Cap | 956.99M |
| Vol | 2.06M | Avg Vol | 1.74M | EPS | -3.35 | P/E | N/A | Forward P/E | -3.35 |
| Beta | 0.86 | Short Ratio | 3.22 | Inst. Own | 114.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 9.60 | 200-d Avg | 9.46 | 1yr Est | 28.57 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-11-04 | 2025-09 | 0 | N/A | -0.28 | -49.12% |
| 2025-08-07 | 2025-06 | 0.15 | N/A | -0.9 | -600.00% |
| 2025-05-01 | 2025-03 | 0 | N/A | -0.15 | -29.41% |
| 2025-02-26 | 2024-12 | 0 | N/A | 0.41 | 65.08% |
| 2024-11-07 | 2024-09 | 0 | N/A | 0.01 | 1.56% |
| 2024-08-08 | 2024-06 | 0 | N/A | 0.04 | 6.35% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-09 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2024-11-26 | Cantor Fitzgerald | Upgrade | Overweight | |
| 2024-11-22 | B of A Securities | Upgrade | Buy | Buy |
| 2024-11-21 | TD Cowen | Upgrade | Buy | |
| 2024-11-21 | Jefferies | Upgrade | Buy | Buy |
| 2024-11-21 | Cantor Fitzgerald | Upgrade | Overweight |
Profile
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-05-19 | BAIR TERESA BROPHY | Officer | 68.98K | Sale |
| 2024-01-29 | DALE STEPHEN M.D. | Officer | 38.82K | Sale |
| 2024-01-28 | DOYLE THOMAS JAMES | Officer | 48.59K | Sale |
| 2023-01-26 | FLOWERS KIRSTEN | Officer | 20.61K | Sale |
| 2024-11-17 | FORD KATHLEEN | Chief Operating Officer | 23.18K | Sale |
| 2023-06-15 | MALLEY THOMAS ROBERT | Director | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Suvretta Capital Management, LLC | 7.65M | 68.42M | 9.84% |
| 2024-09-29 | Blackrock Inc. | 7.16M | 63.97M | 9.20% |
| 2024-09-29 | EcoR1 Capital, LLC | 5.81M | 51.91M | 7.47% |
| 2024-09-29 | Deerfield Management Company, L.P. (Series C) | 5.41M | 48.38M | 6.96% |
| 2024-09-29 | Paradigm Biocapital Advisors LP | 4.33M | 38.72M | 5.57% |
| 2024-09-29 | Vanguard Group Inc | 4.20M | 37.58M | 5.41% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 2.17M | 19.39M | 2.79% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.87M | 16.76M | 2.41% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 1.19M | 10.64M | 1.53% |
| 2024-09-29 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.05M | 9.43M | 1.36% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 742.43K | 6.64M | 0.95% |
| 2024-07-30 | Franklin Strategic Series-Franklin Small Cap Growth Fund | 686.10K | 6.13M | 0.88% |